Robert Jr. Baltera Purchases 10,000 Shares of Palisade Bio (NASDAQ:PALI) Stock

Palisade Bio, Inc. (NASDAQ:PALI) Director Robert Jr. Baltera acquired 10,000 shares of Palisade Bio stock in a transaction on Thursday, July 2nd. The shares were bought at an average price of $1.98 per share, for a total transaction of $19,800.00. Following the completion of the purchase, the director directly owned 366,904 shares in the company, valued at $726,469.92. The trade was a 2.80% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Robert Jr. Baltera also recently made the following trade(s):

• On Wednesday, July 1st, Robert Jr. Baltera purchased 20,000 shares of Palisade Bio stock. The shares were acquired at an average cost of $1.98 per share, for a total transaction of $39,600.00.

Palisade Bio Trading Down 2.9%

PALI stock opened at $2.04 on Tuesday. Palisade Bio, Inc. has a 52 week low of $0.53 and a 52 week high of $2.86. The company has a market capitalization of $354.10 million, a price-to-earnings ratio of -2.02 and a beta of 1.50. The firm’s 50-day moving average is $1.91 and its two-hundred day moving average is $1.91.

Palisade Bio (NASDAQ:PALI) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01). On average, equities research analysts predict that Palisade Bio, Inc. will post -0.25 earnings per share for the current year.

Institutional Trading of Palisade Bio

A number of institutional investors have recently added to or reduced their stakes in PALI. Commodore Capital LP bought a new position in shares of Palisade Bio during the 4th quarter valued at $26,896,000. Perceptive Advisors LLC bought a new stake in Palisade Bio in the fourth quarter worth $28,318,000. Artia Global Partners LP acquired a new position in Palisade Bio during the fourth quarter worth $4,682,000. BIT Capital GmbH acquired a new position in Palisade Bio during the fourth quarter worth $717,000. Finally, Creek Drive Management Group LLC bought a new position in Palisade Bio during the fourth quarter valued at about $723,000. 11.79% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages have issued reports on PALI. Weiss Ratings raised shares of Palisade Bio from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, June 29th. Wolfe Research initiated coverage on Palisade Bio in a research note on Thursday, April 9th. They issued an “outperform” rating and a $7.00 price objective for the company. Oppenheimer set a $7.00 price objective on Palisade Bio in a research report on Tuesday, June 30th. Wall Street Zen raised Palisade Bio from a “sell” rating to a “hold” rating in a research note on Sunday. Finally, LADENBURG THALM/SH SH upgraded Palisade Bio to a “strong-buy” rating in a report on Thursday, June 25th. Two research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $8.83.

Palisade Bio Company Profile

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.